Atrial Fibrillation Clinical Trial
Official title:
Surgical or Catheter Ablations in Patients With Lone Atrial Fibrillation: Determination of Acute and Long Term Success Rate (SCALAF Success Trial)
Prospective randomized interventional trial comparing the efficacy of circumferential pulmonary vein ostia ablation using surgical versus catheter techniques in the treatment of paroxysmal atrial fibrillation. Success rate determined by REVEAL-XT (AF implantable monitoring device).
Title: Surgical or Catheter Ablation in patients with Lone Atrial Fibrillation:
determination of acute and long term SUCCESS (SCALAF-success trial).
Background: Anti-arrhythmic drugs are used in daily practice to treat patients with
paroxysmal idiopatic AF. Often the origin of the AF can be found in the muscle sleeves
running up the pulmonary veins. Drug treatment is not always successful and prone to evoke
negative side effects. The surgical MAZE procedure was applied in the past, but this is a
time consuming, cumbersome technique, often associated with significant complications.
Cardiac radio-frequency ablation offers an alternative, easy and less time consuming
treatment: lesions prevent normal electrical wave front propagation and might stop the
continuation of atrial fibrillation wave fronts. Ablation can be implemented by use of
special catheters inserted via the groin or using the Medtronic Cardioblate® Surgical
Ablation System applied via minimal invasive surgical techniques.
Purpose: Compare the effectiveness of pulmonary vein isolation achieved via catheter or via
surgical ablation techniques to treat patients with paroxysmal lone AF.
Study design: A prospective, randomized multi-center interventional study.
Patients: Patients suffering from paroxysmal idiopatic AF (no associated or underlying
structural heart disease) complying with following inclusion criteria:
- minimally one documented AF-episode in the last 6 months;
- refractory to at least 2 class I or III anti-arrhythmic drugs;
- age > 18 year
Intervention: Patients are randomized to either the surgical or the catheter ablation group
and receive the indicated treatment. During the critical assessment period, the patients are
weaned from anti-arrhythmic medication.
Primary endpoint: Reduction in AF occurrence measured by the AF-burden parameter in the
critical period between 3 and 6 months post-ablation. AF burden is measured automatically by
means of the Reveal XT, implanted at study enrolment to document the baseline
characteristics.
Secondary endpoints:
- Failure of therapy requiring re-interventions;
- Duration, burden and costs of ablation procedures:
- Reduction in frequency, duration and level of severity of AF symptoms;
- Occurences of treatments of arrythmic episodes;
- Assessment of AF burden during follow-up period
- Symptoms associated with AF;
- Reduced necessity of anti-arrhythmic or anticoagulant medication;
- Left atrial dimensions and contractility
- Adverse events associated with the ablation therapy;
- Occurrence of other clinical adverse events (TIA, CVA, bleeds, tamponade, MI) at 3, 6,
12 and 24 months of follow up
- Mortality and hospitalisation
Risk assessment: Possible side effects : irregular heart rhythm, pericardial fluid, stroke,
heart infarct, disturbances of the conduction system in the heart, local pain at the site of
incisions, heart failure or reduced pump function of the heart.
Possible benefits: Regulation of the heart rhythm without applying MAZE procedure or opening
of the thorax. Reduction or relief from symptoms associated with AF. Partial or complete
reduction of anti-arrhythmic medication. Control of anti-coagulant medication. Improved
quality of life for the patients.
Visits are planned at study entrance and Reveal XT implant (assessment at baseline,
application of the ablation therapy), discharge from hospital, and at 3, 6, 12 and 24 months
post-ablation.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Terminated |
NCT04115735 -
His Bundle Recording From Subclavian Vein
|
||
Completed |
NCT04571385 -
A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF)
|
Phase 2 | |
Completed |
NCT05366803 -
Women's Health Initiative Silent Atrial Fibrillation Recording Study
|
N/A | |
Completed |
NCT02864758 -
Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
|
||
Recruiting |
NCT05442203 -
Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease
|
N/A | |
Completed |
NCT05599308 -
Evaluation of Blood Pressure Monitor With AFib Screening Feature
|
N/A | |
Completed |
NCT03790917 -
Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
|
||
Enrolling by invitation |
NCT05890274 -
Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO
|
N/A | |
Recruiting |
NCT05266144 -
Atrial Fibrillation Patients Treated With Catheter Ablation
|
||
Recruiting |
NCT05316870 -
Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation
|
N/A | |
Not yet recruiting |
NCT06023784 -
The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Recruiting |
NCT04092985 -
Smart Watch iECG for the Detection of Cardiac Arrhythmias
|
||
Completed |
NCT04087122 -
Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures
|
N/A | |
Completed |
NCT06283654 -
Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
|
||
Recruiting |
NCT05416086 -
iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|
||
Completed |
NCT04546763 -
Study Watch AF Detection At Home
|
||
Completed |
NCT03761394 -
Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke
|
N/A |